 <h1>Congratulations! 🎉 </h1>
    <p style="color:#637381;">All done! You’ve completed another milestone.</p>

To continue, enter your details to log in.

We’ve sent a 6‑digit code to #MAIL_ADDRESS#\nPlease check your inbox or spam folder and enter the code below to continue.

Verification code sent

Thank you for the payment. You can now access {collectionName} by simply clicking the button below.

Yes, you’ve successfully ordered! 🎉

Unlock This Exclusive Course

It seems that your email address is not currently on the authorized access list. Please ensure you are using the email address that was invited, or contact the content owner for assistance.

Verification Required for Access

ATMP Stability Foundations

SLIDE 1 — Opening Hook

SLIDE 2 — Concept Simplified

Regulatory alignment:

Common misconceptions to call out:

10 Key Concepts

Practical Implementation and Risk Management

SLIDE 4 — Practical Application

Step-by-step correct actions:

Risk indicators (warning signs):

Preventive actions:

DO ✓

AVOID ✗

Case Studies and Inspection Readiness

SLIDE 3 — Case Study with Characters and Dialogue

10-POINT AUDIT / INSPECTION CHECKLIST (ATMP Stability — ICH Q1 Annex 3)

Quizzes

SLIDE 5 — Knowledge Check + Takeaways

Part A — Knowledge Check (5 scenario-based MCQs)

Learning Objective

What is your course about?

Who is the mini-course for?

Course Evaluation and Takeaways

Part B — Reflection

Part C — Top 5 Takeaways

Advanced Therapy Medicinal Products (ATMPs), including cell and gene therapies, represent the cutting edge of modern medicine. However, their unique biological complexities and patient-specific variables make traditional small-molecule stability programs obsolete.

Advanced Therapy Medicinal Products (ATMPs), including cell and gene therapies, represent the cutting edge of modern medicine. However, their unique biological complexities and patient-specific variables make traditional small-molecule stability programs obsolete. Welcome to "Designing Stability Programs for ATMPs Under ICH Q1 Guidelines," a comprehensive course specifically designed to help quality assurance, regulatory affairs, and CMC professionals navigate the intricate landscape of ATMP stability.

In this course, you will dive deep into the specific scope of the ICH Q1 (Draft) guidelines and how they apply to cellular therapies, gene therapies, and tissue-engineered products. We will dismantle common industry misconceptions carried over from conventional biologics and replace them with compliant, lifecycle-based approaches. You will learn how to design robust stability workflows, implement scientifically justified stability-indicating assays, and develop foolproof cold-chain and excursion management strategies.

Beyond theory, this course emphasizes practical implementation and risk management. Through realistic case studies, such as release-under-pressure scenarios for autologous products, you will gain the confidence to make risk-based, patient-centric decisions. Finally, you will evaluate your own programs using a structured 10-point audit checklist to ensure total inspection readiness. Enroll today to master ATMP stability, ensure global regulatory harmonization, and ultimately safeguard the critically ill patients who rely on these life-saving therapies.

Designing Stability Programs for ATMPs Under ICH Q1 Guidelines

<div class="simple-box-wrapper">
    <div class="simple-box">
        <div class="column">
            <p>Advanced Therapy Medicinal Products (ATMPs), encompassing cellular therapies, gene therapies, and tissue-engineered products, present unprecedented biological complexities that fundamentally disrupt traditional stability paradigms. Unlike classical small-molecule programs or conventional biologics, ATMPs require specialized handling, stringent temperature controls, and lifecycle-based approaches to maintain critical quality attributes such as living-cell viability and viral genome titre. Navigating these unique patient-specific variables demands a rigorous understanding of the consolidated ICH Q1 (Draft) guidelines and ICH Q12 principles. This course provides a comprehensive framework for designing compliant stability programs tailored specifically to the nuanced regulatory expectations of advanced therapies, ensuring that professionals transitioning into this space can effectively bridge the gap between historical methodologies and modern compliance standards.</p>

<p>Throughout this curriculum, participants will systematically explore the practical implementation and risk management strategies necessary to build robust ATMP stability workflows. The modules critically evaluate starting materials, intermediates, drug substances, and drug products, while addressing common industry misconceptions and the risks of relying on uncharacterized hold times or single-batch data. By examining real-world case studies, including complex release-under-pressure scenarios, and utilizing a structured 10-point audit checklist based on ICH Q1 Annex 3, professionals will develop the acumen to make risk-based, patient-centric decisions. Ultimately, this program equips quality assurance, regulatory affairs, and manufacturing teams with the scientific justification and proactive risk-mitigation strategies required to defend stability data, manage cold-chain logistics, and achieve global regulatory harmonization and inspection readiness.</p>
        </div>
    </div>
</div>
